RESEARCHER PROFILE

Valesca Bukur

← Back to Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

V

Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCancer Genomics and DiagnosticsBreast Cancer Treatment StudiesGlioma Diagnosis and Treatment

Valesca Bukur works in Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cancer Genomics and Diagnostics, Breast Cancer Treatment Studies, Glioma Diagnosis and Treatment. Recorded institutional associations include Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz.

31Publications
4,482Citations
10H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

    2017 · 2,473 citations
  2. Actively personalized vaccination trial for newly diagnosed glioblastoma

    2018 · 935 citations
  3. Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening

    2018 · 362 citations
  4. Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model

    2020 · 210 citations
  5. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models

    2018 · 193 citations
  6. OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation

    2020 · 141 citations
  7. NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells

    2016 · 72 citations
  8. NF‐κB factors control the induction of NFATc1 in B lymphocytes

    2014 · 17 citations
  9. IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

    2017 · 15 citations
  10. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

    2019 · 15 citations
  11. Abstract OT2-06-01: Highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancer

    2019 · 10 citations
  12. TF-FVIIa PAR2-β-Arrestin Signaling Sustains Organ Dysfunction in Coxsackievirus B3 Infection of Mice

    2024 · 8 citations
  13. Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient

    2021 · 6 citations
  14. Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial

    2016 · 5 citations
  15. Abstract CT202: IVAC MUTANOME: Individualized vaccines for the treatment of cancer

    2015 · 4 citations
  16. Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)

    2018 · 4 citations
  17. Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)

    2019 · 3 citations
  18. Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma

    2024 · 3 citations
  19. Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)

    2019 · 2 citations
  20. Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer

    2017 · 2 citations
  21. Correction: Corrigendum: NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells

    2016 · 1 citations
  22. Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma

    2016 · 1 citations
  23. Abstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project

    2015 · 1 citations
  24. Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

    2016 · 0 citations
  25. PO-324 Detection of high-risk prostate cancer biomarkers by RNA sequencing and qPCR method

    2018 · 0 citations

← Return to the university profile